Oxford BioTherapeutics OGAP®-Verify is now more sensitive than Immunohistochemistry (IHC), measuring membrane proteins as low as 50 copies-per-cell in patient biopsies with quantitative mass spectrometry. This removes the ambiguities of IHC antibody specificity and sensitivity OBT will also present two posters focusing on the platform’s capacity to identify novel cancer-specific targets for the development of first-in-class therapies. OBT’s proprietary proteomic discovery